Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United StatesLori Muffly, William A. Wood, Yi‐Bin Chen et al.|Blood|2017Cited by 296
Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and OutcomesRachel Phelan, Mukta Arora, Min Chen et al.|Transplantation and Cellular Therapy|2022Cited by 82
Prevalence of decisional regret among patients who underwent allogeneic hematopoietic stem cell transplantation and associations with quality of life and clinical outcomesRachel Cusatis, Kathryn E. Flynn, Heather R. Tecca et al.|Cancer|2020Cited by 20
Worsening Financial Toxicity Among Patients Receiving Chimeric Antigen Receptor t-Cell (CAR-T) Therapy: A Mixed Methods Longitudinal StudyRachel Cusatis, Surbhi Sidana, Irena Tan et al.|Blood|2021Cited by 19
Health‐related quality of life in reduced‐intensity hematopoietic cell transplantation based on donor availability in patients aged 50–75 with advanced myelodysplastic syndrome: <scp>BMT CTN</scp> 1102Rachel Cusatis, Kathryn E. Flynn, Michael J. Martens et al.|American Journal of Hematology|2022Cited by 19